Scarica l'app Stockscreener
2.83
5.99%
0.16
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CABA Giù?
Forum
Previsione
Precedente Chiudi:
$2.67
Aprire:
$2.61
Volume 24 ore:
3.51M
Relative Volume:
0.73
Capitalizzazione di mercato:
$461.45M
Reddito:
-
Utile/perdita netta:
$-175.43M
Rapporto P/E:
-1.4339
EPS:
-1.9736
Flusso di cassa netto:
$-143.28M
1 W Prestazione:
-4.87%
1M Prestazione:
-0.35%
6M Prestazione:
+28.64%
1 anno Prestazione:
+68.45%
Intervallo 1D:
$2.60
$2.86
Intervallo di 1 settimana:
$2.59
$2.96
Portata 52W:
$1.26
$4.23
Cabaletta Bio Inc Stock (CABA) Company Profile
Nome
Cabaletta Bio Inc
Settore
Industria
Telefono
(267) 759-3100
Indirizzo
2929 ARCH STREET, PHILADELPHIA, PA
Compare CABA vs VRTX, REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CABA
Cabaletta Bio Inc
|
2.83 | 435.36M | 0 | -175.43M | -143.28M | -1.9736 |
VRTX
Vertex Pharmaceuticals Inc
|
485.65 | 123.36B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.69 | 71.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
860.55 | 53.68B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
186.16 | 38.09B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
267.47 | 37.80B | 4.29B | 577.22M | 641.34M | 4.2086 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-10 | Ripresa | Jefferies | Buy |
| 2024-12-20 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-12-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-10-10 | Iniziato | UBS | Buy |
| 2024-02-05 | Iniziato | Jefferies | Buy |
| 2023-11-29 | Iniziato | William Blair | Outperform |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-19 | Iniziato | Stifel | Buy |
| 2023-09-05 | Iniziato | Citigroup | Buy |
| 2023-07-18 | Iniziato | Guggenheim | Buy |
| 2023-01-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-08-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-08 | Iniziato | Wells Fargo | Overweight |
| 2021-10-19 | Ripresa | Morgan Stanley | Overweight |
| 2021-06-30 | Iniziato | Mizuho | Buy |
| 2021-01-08 | Iniziato | Chardan Capital Markets | Buy |
| 2020-10-13 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-19 | Iniziato | Cowen | Outperform |
| 2019-11-19 | Iniziato | Evercore ISI | Outperform |
| 2019-11-19 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Cabaletta Bio Inc Borsa (CABA) Ultime notizie
ETFs Investing in Cabaletta Bio, Inc. Stocks - TradingView
CABA Stock On Track For Best Day In 6 Months After Positive Early Results From Cell Therapy Trial - Stocktwits
Cabaletta Bio : CABA - 24/7 Wall St.
symbol__ Stock Quote Price and Forecast - CNN
Price to earnings forward of Cabaletta Bio, Inc. – NASDAQ:CABA - TradingView
Cabaletta Bio Inc (CABA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cabaletta Bio (CABA) Rallies 2.82% as Biotech Sector Sentiment ImprovesDip Buy Trade - dars.gov.et
Enterprise value to EBIT forward of Cabaletta Bio, Inc. – NASDAQ:CABA - TradingView
Cabaletta Bio Inc (CABA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cabaletta Bio Inc. (CABA) Q1 2026 Earnings: Narrower-than-Feared Loss Drives Positive Investor SentimentManagement Guidance Update - dars.gov.et
CABA Stock Draws Scrutiny As Ownership Filings Shift - timothysykes.com
Cabaletta Bio Inc (CABA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cabaletta Bio Inc (CABA) Institutional Confidence - TradingKey
Cabaletta Bio Inc (CABA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cabaletta Bio Inc (CABA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Certain Common Stock of Cabaletta Bio, Inc. are subject to a Lock-Up Agreement Ending on 4-JUL-2026. - marketscreener.com
Certain Stock Options of Cabaletta Bio, Inc. are subject to a Lock-Up Agreement Ending on 4-JUL-2026. - marketscreener.com
Cabaletta Bio (CABA) Stock Forecast & Analyst Ratings - Moomoo
Cabaletta Bio(CABA) Stock Options Chain | Quotes & News - Moomoo
Cabaletta Bio, Inc.(NasdaqGS:CABA) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Cabaletta Bio, Inc.(NasdaqGS: CABA) added to Russell 2500 Growth Benchmark - marketscreener.com
Cabaletta Bio, Inc.(NasdaqGS: CABA) added to Russell 2000 Index - marketscreener.com
Cabaletta Bio, Inc.(NasdaqGS: CABA) added to Russell 2000 Value Benchmark - marketscreener.com
Cabaletta Bio, Inc.(NasdaqGS: CABA) added to Russell 2000 Growth Benchmark - marketscreener.com
Cabaletta Bio, Inc.(NasdaqGS: CABA) added to Russell 3000E Growth Benchmark - marketscreener.com
Cabaletta Bio, Inc.(NasdaqGS: CABA) added to Russell 3000E Index - marketscreener.com
Cabaletta Bio, Inc.(NasdaqGS: CABA) added to Russell 3000E Value Benchmark - marketscreener.com
Cabaletta Bio, Inc.(NasdaqGS: CABA) added to Russell 2500 Index - marketscreener.com
Cabaletta Bio: The Market Sold The EULAR News, I'm Buying (NASDAQ:CABA) - Seeking Alpha
Cabaletta Bio, Inc. Actuals & Estimates (NASDAQ:CABA) - TradingView
CABA Forecast — Price Target — Prediction for 2027 - TradingView
CABACabaletta Bio Inc Volatility & Greeks - Finviz
Cabaletta Bio Hits Reset on RESET-MS Trial, Narrowing Near-Term Upside in Multiple Sclerosis - TipRanks
Cabaletta Bio (CABA) upgraded to buy: Here's why - MSN
Cabaletta Bio (CABA) Edges Higher Amid Sector Volatility: Support and Resistance Levels in FocusATR Stop - dars.gov.et
Cabaletta Bio, Inc.(NasdaqGS: CABA) added to S&P Biotechnology Select Industry Index - marketscreener.com
Cabaletta Bio Inc (CABA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cabaletta Bio Inc (CABA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cabaletta Bio Inc (CABA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
How Cabaletta Bio (CABA) Is Turning Rese-cel Enrollment and New Financing Into a Clearer Autoimmune Cell Therapy Setup - Insider Monkey
CABA Technical Analysis & Stock Price Forecast - Intellectia AI
5 Small Cap Stocks with Potential to Rise 1000 Percent - Insider Monkey
Cabaletta Bio Shareholders Approve Share Increase and Directors - The Globe and Mail
Cabaletta Bio (CABA) Proxy filing Summary - Quartr
Cabaletta Bio (NASDAQ: CABA) doubles authorized common shares - Stock Titan
[Form 4] Cabaletta Bio, Inc. Insider Trading Activity - Stock Titan
Director at Cabaletta Bio (CABA) receives grant of 22,000 stock options - Stock Titan
Cabaletta Bio (CABA) director receives stock options for 22,000 shares at $3.22 - Stock Titan
Cabaletta Bio | 4: Statement of changes in beneficial ownership of securities-Director Bollard Catherine - Moomoo
Cabaletta Bio (CABA) director Catherine Bollard receives 22,000 stock options at $3.22 - Stock Titan
Cabaletta Bio Inc Azioni (CABA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Cabaletta Bio Inc Azioni (CABA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Binder Gwendolyn | President, Science & Tech. |
Jan 21 '26 |
Buy |
2.19 |
11,312 |
24,763 |
31,312 |
| Tomasello Shawn | Director |
Jan 21 '26 |
Buy |
2.21 |
22,725 |
50,322 |
22,725 |
| Gavel Steve | Chief Commercial Officer |
Jan 21 '26 |
Buy |
2.27 |
22,170 |
50,215 |
22,170 |
| Bollard Catherine | Director |
Jan 21 '26 |
Buy |
2.27 |
4,405 |
9,982 |
5,405 |
| Nichtberger Steven | President & CEO |
Jan 21 '26 |
Buy |
2.24 |
45,000 |
100,778 |
1,031,483 |
| Simon Mark | Director |
Jan 21 '26 |
Buy |
2.28 |
11,061 |
25,261 |
147,205 |
| Gerard Michael | General Counsel |
Jan 21 '26 |
Buy |
2.27 |
6,600 |
14,979 |
6,600 |
0.80%
2.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):